• Other
  • Exited

Building an enduring biopharmaceutical company with compounds from our own research efforts that represent significant advances in the fields of thrombosis and other hematologic diseases. Our development-stage portfolio includes three 100 percent-owned clinical-stage assets and one partnered program. Each of our therapies has the potential to address a significant unmet need